Rupa Huq MP: speeches

Speeches

• 17 Jun 2025 · Prostate Cancer Treatment · Hansard source

  More

  Yes, I will. What an honour to give way to the hon. Member for Strangford (Jim Shannon)!

• 17 Jun 2025 · Prostate Cancer Treatment · Hansard source

  More

  I totally agree. West London needs the same as the west of Scotland, the west of Wales, and all the other bits of those other nations. Men can access abiraterone on the NHS in Scotland and Wales, but not in England, even with an identical diagnosis. It seems at best anomalous that their postcode, not their prognosis, is determining their treatment, and we all know that the NHS is meant to be free at the point of need. I would give anything to have had longer with my dad. I was reminded of him when, like the hon. Member for Harrogate and Knaresborough (Tom Gordon), I had someone come to see me: Peter Treadgold, who came to my advice surgery and pointed out that he is falling between the cracks. He had a long-standing diagnosis, with remission, and he diligently followed all the advice. He was under NHS monitoring for 20 years because he had heightened prostate-specific antigen levels, although he was never actually offered an MRI or ultrasound scan. Last year, his cancer came back, and he was told that he would need hormone and radiation therapy; abiraterone was not offered. Peter is one of the one in three people who get the devastating news that their cancer has come back, and has been denied access to a treatment that could save or extend his life. The first time I heard of abiraterone was when I met Peter, because as my hon. Friend the Member for Uxbridge and South Ruislip (Danny Beales) said, in my dad’s day, it would not have been cost-efficient. However, it is now a generic drug—it has gone off patent—but it is licensed only for metastatic cases. As my hon. Friend the Minister knows well, there is a complicated, convoluted process involved in getting it approved for non-metastatic cases. There is no question about the effectiveness of abiraterone. It has had one of the biggest trials known to mankind, a genuinely world-beating trial. When NHS England’s own clinical priorities advisory group plotted the clinical benefit against the net cost, abiraterone scored highest in that tabulation. It is calculated that two years of abiraterone treatment would halve the death rate for men with locally advanced prostate cancer, but we hear about budgetary challenges. I have written to the Minister and tabled questions, and have been told that NHS England has not identified the recurrent budget to support provision of the drug. We should look long-term, at the remissions, and at the cost of chemotherapy, hospital appointments and other associated things. Those costs add up. University College London found that abiraterone would pay for itself if it were £11 a day. Do Members know what the NHS is actually paying? Does anyone want to hazard a guess? Oh, we are not doing call and response. Abiraterone costs £2.75 a day, now that it is off patent and has come down in price. That is less than three measly quid to avoid costly relapses, scans, chemo, hospital appointments and everything else—less than three little round ones to improve lives and reduce deaths. As we have heard, only people who can fork out up front for private treatment or private medical insurance currently have that option, and again, our NHS was not meant to be for private profiteering or big pharma drug pushers. People are seeing their pensions and life savings evaporate, and we are in a cost of living crisis. This drug should be universally available. It took less than one year for abiraterone to be approved for men with non-metastatic prostate cancer in Scotland and Wales. In England, it is now three years and counting, and we still have not had a concrete resolution. Right now, abiraterone is the cheapest and most cost-effective it has ever been, and as the excellent Prostate Cancer UK put it, the postcode lottery must end. Lord Darzi’s independent investigations into the NHS found that the UK had higher cancer mortality rates than other comparable countries, and sadly, progress in diagnosing cancer at stages 1 and 2 is flatlining. Just over half of prostate cancers are caught at an early stage. That falls well short of the NHS target of 75%. I appreciate that Labour has just come into power after 14 years of the Conservative party, so it will take time to fix our health system, but we need it to be more responsive—to act early and rapidly, to use all the tools it can, and to offer preventive rather than after-the-fact care in every case. Abiraterone exemplifies all those things. I welcome the Chancellor’s 3% real-terms increase in NHS spending to deliver the exciting plan to build an NHS fit for the future. With the 10-year plan coming soon and the national cancer strategy due this autumn, we have a real chance to deliver significant improvements for people living with cancer, so as is customary, I have a list of questions for the Minister. I will incorporate those of my hon. Friends—I think we are all friends here, even if we sit on opposite sides of the Chamber. First, will the Minister commit to exploring ways of ensuring that additional NHS funding is used to make abiraterone available to all men who need it in England—and in Northern Ireland, as the hon. Member for Strangford (Jim Shannon) has pointed out? Secondly, will the Minister support the introduction of a national programme of screening for prostate cancer, like those that we have for comparable cancers in the United Kingdom? Thirdly, given the complexity of NHS England’s decision-making processes in relation to the availability of abiraterone—which sound like a right old bureaucratic nightmare—as the functions of NHS England are transferred back to the Department of Health and Social Care, will the Minister take steps to ensure that all decisions about access to medicine, including abiraterone, are timely and transparent? I know that she has had a long career in the NHS, and as I have said, she is on the side of the angels. Fourthly, will the Minister commit to publishing an equality impact assessment, given the disturbingly disproportionate effect that prostate cancer is having on black men, who are more likely to develop it and to receive a late diagnosis, and less likely to receive the right treatment? I am doing this partly for Dad, who is watching from somewhere up above, but also for the black and minority ethnic men who are implicated here and now. This is the second time that you have been in the Chair, Madam Deputy Speaker, when I have been talking about health inequalities since Friday, when we discussed assisted dying. You have chaired both debates excellently. Fifthly, in the light of the lengthy approval process, will the Minister assess the adequacy of the funding formula model—we have NICE and we have the Medicines and Healthcare products Regulatory Agency, and it all seems a bit knotty—and consider whether novel pharmaceutical treatments could be produced cost-effectively, especially, as my hon. Friend the Member for Uxbridge and South Ruislip said, when they come off-patent. I am arguing for simplification in cases in which drugs are already prescribed for limited use and there is a credible case for expanding their application to a generic treatment. We are halfway there; we just need to go that little bit further. Prostate Cancer UK estimates that 672 men die prematurely each year because we have no access to abiraterone. Each week that this continues, 13 men in England will die from a cancer that could have been treated cheaply had they lived in Scotland or Wales. Labour is the party of the NHS, and a Labour Government introduced the UK’s first dedicated cancer strategy; so let us go for this win-win for all, end the iniquitous, unjust postcode lottery, celebrate the best of British science, and widen access to abiraterone for all those who need it, not just those who can afford it.

• 17 Jun 2025 · Prostate Cancer Treatment · Hansard source

  More

  I completely agree with the hon. Gentleman that access should be based not on how deep somebody’s pockets are, but on need. Abiraterone halves the risk of relapse. Each relapse literally costs the NHS millions—the definition of lose-lose. As many Members have pointed out, it is already successfully available on the NHS and routinely funded for use in metastatic cases in England, but sadly there is a catch: abiraterone is not available on the NHS for men with non-metastatic prostate cancer living in England.

• 17 Jun 2025 · Prostate Cancer Treatment · Hansard source

  More

  The hon. Member reads my mind about the postcode lottery, which I will come to in my list of questions. I know that my hon. Friend the Minister is very sympathetic and on the right side. Abiraterone is now a global drug. Half a million men around the world have had transformed outcomes, improved quality of life and extra years spent with loved ones.

• 17 Jun 2025 · Prostate Cancer Treatment · Hansard source

  More

  Joe Biden’s recent diagnosis has to some extent put prostate cancer in the spotlight of late, but it is not just him—there is Stephen Fry, Jools Holland and Robert De Niro. More than 50,000 men in the UK and 1.4 million men worldwide are diagnosed with prostate cancer yearly, which is projected to double by 2040. With one in eight men diagnosed during their life, it is the most common male cancer. More than half of those men are pre-retirement age, such as the cyclist Sir Chris Hoy, who was diagnosed at 48, but 70-plus is the most common age. My late dad was 69 when he was diagnosed. He left this earth just shy of his 79th birthday in August 2014, so he had 10 years. It is often said that men die with prostate cancer, not of it. With my dad, it spread to bone cancer, but pneumonia was actually the cause of death on the certificate. I miss him every day. Treatment for prostate cancer has improved dramatically since then. One crucial breakthrough is the development of the drug abiraterone, a Great British success story discovered and initially developed in London at the Institute of Cancer Research. It is a shining example of British science leading the world and revolutionising advanced prostate cancer care.

• 16 Jun 2025 · Iran-Israel Conflict · Hansard source

  More

  Ealing has long had a big Iranian diaspora. In 1978, when England did not qualify in the world cup and Iran did, a lot of my classmates were supporting the latter; now, they are my adult constituents, and they have been caught up in all this. Could my right hon. Friend tell me what steps he is taking to ensure the safe passage of our constituents back home, including one of my constituents, who needs to resume her cancer treatment and wants urgently to come back to England?

• 13 Jun 2025 · Terminally Ill Adults (End of Life) Bill · Hansard source

  More

  I totally agree. We know that Esther Rantzen and Jonathan Dimbleby want the Bill to be implemented, but our role is to be voices for the voiceless, so I totally agree with her. As opposed to the vague, ever-changing qualifying criteria that are held up as safeguards, at least these amendments would put ethnic minority people on the board: new clause 6 says that if they are on the ward, they should be on the board as well. The Bill seems to have neglected them altogether, so the new clause would provide real protections. We know that in a cost of living crisis, assisted dying could be quite attractive. BAME communities have lower disposable household incomes than standard households, and during a cost of living and housing crisis, it is possible to imagine relatives wanting to speed up granny or grandad’s probate—or naani maa or dadima, even—to get a foot on the ladder.

• 13 Jun 2025 · Terminally Ill Adults (End of Life) Bill · Hansard source

  More

  No, because I will not get any more time. Given the cost of care, people could convince themselves that elderly relatives would be better off out of the way, in order to get the younger generation on the ladder. We know from the experience of other places that once assisted dying is allowed, the scope broadens—depressed 12-year-olds in Holland can get it—and the incentive to fix palliative care will lessen. Why now, with the state of the NHS? What of Suicide Prevention Week? Yes, we know that public opinion is in favour of assisted dying, but public opinion also supports bringing back hanging.

• 13 Jun 2025 · Terminally Ill Adults (End of Life) Bill · Hansard source

  More

  I rise to support amendments 34 to 36 and new clause 6, tabled by my right hon. Friend the Member for Walsall and Bloxwich (Valerie Vaz), who sadly cannot be here today. Health inequality shapes life expectancy and outcomes —covid deaths illuminated that—but it is absent from the Bill. A younger me would have been 100% behind this Bill. I am very pro body autonomy when it comes to abortion, but 10 years of being an MP has exposed me to coercion, duress, the billionaire price of London property, and elder abuse. It is no coincidence that, like me, the majority of London MPs and of black and minority ethnic MPs oppose the Bill. Let us look at amendment 34. The experience of my aged parents—now no longer with us—opened my eyes to a world of pills, incontinence pads, hoists, power of attorney, key safe boxes and carer worries. I saw how non-native English-speaking pensioners—I am not talking about Welsh speakers—have their agency denied, perhaps unconsciously, by health professionals in a stretched system. My mum’s GP had a clear contempt for her accented words. At every appointment she would say to her, “One question only”. As my mum grew frailer and began to lose the power of speech, she reverted to her mother tongue and was seen by hospital teams as an annoyance, a time waster, and bed blocker. Similarly, the disabled are often written off. People cannot see beyond the wheelchair or the non-verbal. Amendment 34 would place a duty on the chief medical officer to provide information at every step of the way

• 13 Jun 2025 · Terminally Ill Adults (End of Life) Bill · Hansard source

  More

  No, I am not giving way. At my advice surgery, people have pointed out the unfairness of the £10,000 cost of Dignitas. We know that the status quo is imperfect, but let us not remedy it with something that will make things worse. We need to get this 100% right if we are going to do it all. Although well intentioned, the Bill has too much room for error, manipulation, misapplication and unintended consequences. Six months to live is impossible to predict and, with life and death, it is too late to change your mind after the latter has happened, is it not? This week, 1,000 doctors have argued that it will widen inequalities and it is simply not safe. These amendments strengthen the Bill by taking ethnic minorities into account, when hitherto they have been completely unacknowledged by it. They must be incorporated into any assisted dying legislation, but the best thing of all would be not to rush down this road with indecent haste in the first place, because it is so littered with obstacles.

• 13 Jun 2025 · Terminally Ill Adults (End of Life) Bill · Hansard source

  More

  Will I get more time? [ Laughter . ]

• 11 Jun 2025 · NHS Funding: South-west · Hansard source

  More

  Order. I call the shadow Minister.

• 11 Jun 2025 · NHS Funding: South-west · Hansard source

  More

  Order. I think that someone will probably end up falling off the call list; there are people standing to speak who were not on the list and who were not standing at the beginning of the debate. Let us see how we go.

• 11 Jun 2025 · NHS Funding: South-west · Hansard source

  More

  Order. Given how many people wish to speak, we will start with a two and a half minute limit.

• 11 Jun 2025 · NHS Funding: South-west · Hansard source

  More

  Order. I am afraid that we will now move on to the Front Benchers, starting with the Liberal Democrat spokesperson.

• 11 Jun 2025 · NHS Funding: South-west · Hansard source

  More

  The aim is to take the three Front Benchers from 5.09 pm, which means that the time limit is dropping down to two minutes each.

• 11 Jun 2025 · Child Poverty and No Recourse to Public Funds · Hansard source

  More

  Order. A number of Members are bobbing, so we will calculate how long everyone will get. To start, I call Kirsty Blackman.

• 11 Jun 2025 · Child Poverty and No Recourse to Public Funds · Hansard source

  More

  I call Keir Mather MP, who is making his Westminster Hall Dispatch Box debut as Minister for the day.

• 11 Jun 2025 · Child Poverty and No Recourse to Public Funds · Hansard source

  More

  Actual Minister!

• 11 Jun 2025 · Outdoor Education · Hansard source

  More

  I will call Tim Farron to move the motion. As is the convention with 30-minute debates, only interventions are permitted, not whole speeches, because we need to allow time for the Minister to reply, as well as for all those lovely interventions that are coming.

• 11 Jun 2025 · Outdoor Education · Hansard source

  More

  indicated dissent.

• 20 May 2025 · UK-EU Summit · Hansard source

  More

  It is brilliant that the Brexit logjam that has cast a long shadow over this House for so many years has been smashed by this Prime Minister. Could he indicate when we might hear a bit more about the youth experience scheme that has been so yearned for and so welcomed by the universities and the English language teaching sector, and also by my staff, team and son, who were born too late to have a say in any of the mess that the Tories left behind?

• 14 May 2025 · Gaza: UK Assessment · Hansard source

  More

  The Minister, who is a good man, recognises that the 70-day aid blockade has made starvation widespread in Gaza. During the recess, I was on a delegation with the hon. Member for Strangford (Jim Shannon). We were nearby in Egypt, and we heard real fears that annexation of both Gaza and the west bank is near-inevitable. The Minister has told us what steps he has taken up until now, but there has been a clear escalation, so can he please give us some hope that there are further levers that can be pulled? We do not want to be on the wrong side of history.

• 12 May 2025 · Topical Questions · Hansard source

  More

  T5. My constituent Charlie Vernon was happily benefiting from the Access to Work scheme until redundancy. He found a new job and did a fresh application last autumn, but since then, well beyond the 24-week timeframe, there has been nothing. Will my right hon. Friend look into these sorts of delays and have a more joined-up system, because assessors are apparently dealing with applications from August at the moment?

• 1 May 2025 · Parkinson’s Awareness Month · Hansard source

  More

  My hon. Friend is making a powerful speech about this very complex condition. He mentioned Rory Cellan-Jones, who is well known as a BBC technology correspondent and, as the person who houses Sophie from Romania, a famous dog lover. He is my constituent in Ealing. I totally agree with my hon. Friend; the “Movers and Shakers” podcast, which won the Broadcasting Press Guild’s best podcast of the year award, has shown with such humanity and warmth the ups and downs—a lot of downs—of this very sad condition, which is growing. I assure the 153,000 sufferers in this country and the 10 million worldwide that today’s attendance is a reflection not of the importance of this debate, but of electoral events outside this House. Does my hon. Friend agree that the Parky charter to encourage more research into this terrible condition that afflicts so many, which Rory lobbies me quite often about, deserves Government funding? I hope that my hon. Friend the Minister on the Treasury Bench is also listening.